FactaeThe Factual News

Milvexian fails in post-acute coronary syndrome but offers new avenues

A clinical trial on milvexian after acute coronary syndrome shows no efficacy.

Published 3h1 sourceNotableupdated 2h
Lire en français
≈ 16s

The fact

The drug may still be useful in other thrombotic indications.

Researchers are now exploring new applications for this molecule.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on August 29, 2026
← Back to home
Discover

Read more

All sante →
science

Anticancer drug could address a global health threat

10sem · 1 sourcesante

Clopidogrel more effective than aspirin after coronary angioplasty

14sem · 1 sourcesante

Coronary trunk stenosis: bypass and medical treatment on equal footing

12sem · 1 sourcesante

Experimental drug offers new hope against resistant hypertension

5sem · 1 sourcesante

Major review questions real-world benefits of breakthrough Alzheimer's drugs

19sem · 1 sourcesante

Stable patients can discontinue beta-blockers after myocardial infarction

17sem · 1 source